Innorna Earns Nomination for 2026 Prix Galien USA Best Startup Award
Innorna and Its Notable Nomination for the Prix Galien
On August 13, 2026, Innorna, a pioneering biotech company specializing in RNA therapeutics, proudly announced its nomination for the esteemed 2026 Prix Galien USA Best Startup Award. This recognition highlights Innorna's innovation within the biotechnology industry, particularly its advancements in RNA medicines.
Innorna has been shortlisted in the Best Startup category for its cutting-edge mRNA-LNP (lipid nanoparticle) platform which has demonstrated remarkable capabilities. The company's ongoing clinical research has gone beyond conventional vaccine development and is now paving the way for new therapeutic options. Their flagship program, known as IN026, is an innovative mRNA therapy specifically designed to combat refractory gout by effectively lowering uric acid levels. Following the FDA's Investigational New Drug (IND) clearance received in March 2026, Innorna has expanded the potential of mRNA technology into managing chronic diseases, thus changing paradigms within the medical field.
The Prix Galien is often described as the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.